5 recruiting, 4 active not recruiting, 2 withdrawn, 1 suspended. 7 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Active not recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 6 | Active not recruiting 3, Withdrawn 2, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Platinum-Resistant Ovarian Carcinoma: new trials by email Literature Review of Recurrent Platinum-Resistant Ovarian Carcinoma trials Research Report on Recurrent Platinum-Resistant Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer DT2216, Paclitaxel - Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Recruiting | Elizabeth Stover, MD, PhD | 30 | 2025-09-22 | 2026-09-11 |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 65 | 2023-12-18 | 2026-10-27 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Suspended | National Cancer Institute (NCI) | 66 | 2022-02-02 | 2026-08-17 |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer Abemaciclib, Biopsy Procedure, Biospecimen Collection - Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2021-07-02 | 2026-09-11 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab - Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 29 | 2018-02-01 | 2026-07-16 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-26 |
Ovarian Neoplasms (5) · Fallopian Tube Neoplasms (4) · Endometrial Neoplasms (2) · Carcinosarcoma (1) · Neoplasm Metastasis (1)
Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Neoplasms (7) · Neoplasms by Site (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Adnexal Diseases (6) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Gonadal Disorders (5) · Ovarian Diseases (5) · Fallopian Tube Diseases (4)
Magnetic Resonance Spectroscopy (7) · Specimen Handling (7) · Biopsy (4) · Disulfides (4) · Immunoglobulin G (4) · Paclitaxel (4) · Bevacizumab (3) · Doxorubicin (3) · Taxes (3) · liposomal doxorubicin (3) · olaparib (3) · Phantoms, Imaging (2) · Topotecan (2) · X-Rays (2) · pembrolizumab (2)
National Cancer Institute (NCI) (8) · City of Hope Medical Center (1) · Elizabeth Stover, MD, PhD (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (11) · Puerto Rico (2)
Brenda J. Ernst, M.D. (1) · Camille Jackson (1) · Elizabeth Stover, MD, PhD (1) · Emese Zsiros (1) · Fiona Simpkins (1) · Haider S Mahdi (1) · Joyce F Liu (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Panagiotis A Konstantinopoulos (1) · Roisin E O'Cearbhaill (1) · Thanh Dellinger (1)
U10CA180868 (5), P30CA033572 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186709 (1)